Krebs Biochemicals and Industries Limited

Krebs Biochemicals: All 5 Resolutions Passed at 34th AGM on Sept 29, 2026

Krebs Biochemicals' 34th AGM on September 29, 2026, saw all five ordinary resolutions passed. These included financial statement adoption, director re-appointments, related party transactions with IPCA Laboratories, and cost auditor remuneration ratification.

Krebs Biochemicals holds 34th AGM on Sep 29, 2026, discusses financial statements and RPTs.

Krebs Biochemicals & Industries Limited conducted its 34th AGM on September 29, 2026. Key agenda items included approving financial statements for FY26, reappointing directors, and approving related party transactions with Ipca Laboratories Limited. E-voting was conducted from September 25-28, 2026.

Krebs Biochemicals: Trading Window Closed Sep 30 for Q2 FY27 Results

Krebs Biochemicals & Industries Limited will close its trading window from September 30, 2026, for its Q2 FY27 financial results. The window will reopen 48 hours after results declaration, impacting promoters, directors, and connected persons.

Krebs Biochemicals Q1 FY27 Unaudited Results: Net Loss Widens to ₹248.48 Lacs

Krebs Biochemicals reported Q1 FY27 un-audited results with revenue from operations at ₹698.35 lacs. The company posted a net loss of ₹248.48 lacs for the quarter ended June 30, 2026, compared to a loss of ₹532.43 lacs in Q1 FY26. The Board approved the results on August 6, 2026. The amalgamation with IPCA Laboratories is proceeding.

Krebs Biochemicals announces 34th AGM on Sep 29, 2026, with e-voting from Sep 25-28.

Krebs Biochemicals and Industries Limited will hold its 34th Annual General Meeting on September 29, 2026. E-voting will be available from September 25 to September 28, 2026. The Annual Report for FY2025-26 is available on the company and stock exchange websites.

Krebs Biochemicals to hold 34th AGM on Sep 29, 2026, with e-voting facility

Krebs Biochemicals will hold its 34th AGM on September 29, 2026, via VC/OAVM. Shareholders can e-vote from September 25-28, 2026. The agenda includes approving FY26 financial statements, re-appointing directors, and seeking approval for related party transactions up to ₹120 crore with Ipca Laboratories.

Krebs Biochemicals Announces 34th AGM on Sep 29, 2026

Krebs Biochemicals & Industries Limited will hold its 34th AGM on September 29, 2026, at 11:30 AM IST via VC/OAVM. The annual report and financial statements for FY2025-26 will be emailed to shareholders and available online. E-voting facilities will be provided.

Krebs Biochemicals Q1 FY27 Unaudited Results Declared

Krebs Biochemicals reported Q1 FY27 un-audited results. Total income was ₹714.00 lakhs. Net loss after tax was ₹248.48 lakhs, compared to a loss of ₹233.96 lakhs in Q1 FY26. Basic and diluted EPS stood at ₹(1.15) for Q1 FY27.

Krebs Biochemicals Q1 FY27 Unaudited Results Approved by Board

Krebs Biochemicals and Industries Limited's Board approved the Unaudited Financial Results for Q1 FY27 ended June 30, 2026. The Limited Review Report from the auditors was also approved during the Board meeting held on August 6, 2026.

Krebs Biochemicals submits SEBI Reg 74(5) certificate for Q1FY27

Krebs Biochemicals & Industries Limited submitted its SEBI Regulation 74(5) certificate for the quarter ended June 30, 2026. The certificate confirms dematerialization/rematerialization details were provided to stock exchanges by the Registrar & Share Transfer Agent, KFIN Technologies Limited.

Krebs Biochemicals: Trading Window Closed June 30, 2026 for Q1 FY27 Results

Krebs Biochemicals will close its trading window from June 30, 2026, until 48 hours after the declaration of Q1 FY27 unaudited financial results. This applies to insiders and connected persons.

Krebs Biochemicals publishes Q4 & FY26 Audited Financial Results

Krebs Biochemicals & Industries Limited reported audited financial results for Q4 FY26. The company posted a net loss of ₹233.96 Lakhs for the quarter and ₹2,693.93 Lakhs for the full year. Total income from operations for Q4 FY26 was ₹881.27 Lakhs.

Krebs Biochemicals reports Q4 & FY26 results; net loss narrows

Krebs Biochemicals & Industries Limited declared its audited financial results for Q4 and FY26 ending March 31, 2026. The company reported a loss before tax of ₹233.96 lacs for the quarter and ₹1693.31 lacs for the year. The statutory auditors issued an unmodified report.

Krebs Biochemicals Clarifies No Material Event Impacting Price Movement

Krebs Biochemicals & Industries Limited clarified to NSE that no material events requiring disclosure have occurred that would explain the recent significant price movement in its securities. The company confirmed compliance with SEBI regulations.

Krebs Biochemicals Promoters Declare No Encumbrance on Shares

Ipca Laboratories Limited, a promoter of Krebs Biochemicals & Industries Ltd., declared no encumbrance on equity shares for FY26. The declaration was made on April 2, 2026, as per SEBI Takeover Regulations.

Krebs Biochemicals: Certificate under SEBI Reg. 74(5) for Q4FY26

Krebs Biochemicals & Industries Limited submitted a certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The certificate, received from RTA KFIN Technologies, confirms dematerialization/rematerialization details were furnished to stock exchanges.

Krebs Biochemicals: Trading Window Closed from March 31, 2026 for FY26 Audited Results

Krebs Biochemicals will close its trading window from March 31, 2026. This closure is in anticipation of the declaration of audited financial results for the fourth quarter and year ended March 31, 2026. The window will reopen 48 hours after the results announcement.

Krebs Biochemicals Publishes Q3 FY26 Unaudited Financial Results

Krebs Biochemicals published its unaudited Q3 FY26 results on February 10, 2026. The company reported a net loss of ₹2,081.03 lakh for the nine months ended December 31, 2025, an improvement from ₹2,702.22 lakh in the prior year. Loss per share improved to ₹12.49 from ₹14.28.

Krebs Biochemicals Q3 FY26: Net Loss Widens to ₹312.65 Lakhs

Krebs Biochemicals reported unaudited results for Q3 FY26. The company posted a net loss of ₹312.65 lakhs for the quarter ended December 31, 2025, compared to a loss of ₹614.28 lakhs in the prior quarter. Loss per share for the quarter was ₹1.45. The Vizag manufacturing unit remains closed.

Krebs Biochemicals: No Physical Share Transfer Requests Re-lodged in Special Window

Krebs Biochemicals & Industries Limited reported no physical share transfer requests re-lodged during the SEBI-mandated special window as of December 31, 2025. The Registrar and Share Transfer Agent, KFIN Technologies Limited, confirmed NIL requests received, processed, approved, or rejected.

Krebs Biochemicals submits SEBI compliance certificate for Q3 FY26

Krebs Biochemicals and Industries Limited submitted a certificate under SEBI regulations for the quarter ended December 31, 2025. The company's Registrar and Share Transfer Agent, KFIN Technologies Limited, confirmed that details of securities dematerialization/rematerialization have been furnished to stock exchanges.

Krebs Biochemicals: Trading Window Closure for Q3 FY26 Results Announcement

Krebs Biochemicals will close its trading window from December 31, 2025, until 48 hours after the declaration of Q3 FY26 unaudited financial results. This affects insiders and connected persons. The Board meeting date for results consideration will be announced later.

Re-lodgement of transfer requests of physical shares

Krebs Biochemicals informs about the re-lodgement of physical share transfer requests as of November 30, 2025, following SEBI guidelines. A special window remains open until January 6, 2026.

Re-lodgement of Transfer Requests for Physical Shares

Krebs Biochemicals announces re-lodgement of physical share transfer requests as of October 31, 2025, with a special window open until January 6, 2026. Details are on the company website.

Krebs Biochemicals Reports Q2 FY26 Loss; Unaudited Standalone Results Published

Krebs Biochemicals reported a net loss of ₹614.28 lakhs for Q2 FY26, with total income at ₹417.41 lakhs. The unaudited standalone results for the quarter and half year were approved and published.

Krebs Biochemicals Approves Unaudited Financial Results for Q2 & H1 Ended Sep 2025

Krebs Biochemicals approved unaudited financial results for Q2 and Half year ended September 30, 2025, reporting a loss of ₹532.43 lakhs for the quarter.

Krebs Biochemicals Reports Significant Revenue Decline and Increased Losses for Q2 & H1 FY26

Krebs Biochemicals reported a substantial drop in Q2 and H1 FY26 revenue to ₹4.17 crore and ₹5.48 crore, respectively, with increased losses to ₹(6.14) crore and ₹(11.47) crore. Vizag unit remains closed.

Krebs Biochemicals updates on re-lodgement of physical share transfer requests

Krebs Biochemicals provided an update on re-lodgement of physical share transfer requests as per SEBI circular. No requests were received or processed as of September 30, 2025, during the special window.

Proceedings of 33rd Annual General Meeting

Re-lodgement of transfer requests of physical shares

Krebs Biochemicals to Hold 33rd AGM on Sep 26, 2025; Key Appointments, RPTs, and FY25 Results on Agenda

KREBSBIO fined by NSE and BSE for board composition non-compliance, issue rectified

KREBSBIO: Mr. Manish Kumar Jain Appointed as MD & CEO, Mr. Jitendra Shah Resigns

Krebs Biochemicals MD & CEO Jitendra Shah Resigns Effective August 7, 2025